摘要
目的评价吉非替尼(gefitinib)治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法48例晚期NSCLC患者给予吉非替尼250mg,1/d,口服,疗程2～8个月。回顾性分析其疗效及安全性。结果48例患者有效率35.4%(17/48),其中完全缓解(CR)4.2%(2例)、部分缓解(PR)31.3%(15例);临床控制率为68.8%(33/48),其中有效(CR+PR)35.4%(17例),稳定(SD)33.3%(16例);临床受益反应率为75.0%(36/48)。腺癌组有效率及临床控制率显著优于非腺癌组(P<0.01);男性患者有效率为23.5%(8/34),女性患者有效率为64.3%(9/14),两者比较有统计学差异(P<0.01)。胃肠道不良反应发生率为81.3%(39/48),其中腹泻为38.5%(15/39);皮疹发生率为68.8%(33/48)。结论吉非替尼治疗晚期NSCLC疗效较好,不良反应轻微,值得临床进一步推广。
Objective To evaluate clinical curative effect and safty evaluation of gefitinib in the treatment of NSCLC（nonsmall cell lung cancer）.Methods Fourty eight patients with advanced stage NSCLC were administrated Gefitinib 250 mg daily orally for 2-8months and analysed its curative effect and safty retrospectively.Results The total effective rate was 35.4%（17/48）,including CR of 2 cases（4.2%）and PR of 15 cases（31.3%）;the clinical control rate was 68.8%（33/48）,including effectiveness of 17 cases（35.4%） and SD of 16 cases（33.3%）;the clinical profit reaction rate 75.0%（36/48）.The effective rate and the clinical control rate of adenocarcinoma group were superior than that of non-adenocarcinoma group（P0.01）;The effective rate in the male patients was 23.5%（8/34）,while that in the female patients was 64.3%（9/14）,there was significant different in the effective rate between two group（P0.01）.The adverse reaction of gastrointestinal tract was 81.3%（39/48）,38.5%（15/39）of which was diarrhea;the erythra rate was 68.8%（33/48）.Conclusions Gefitinib have better curative effect and insignificant adverse reaction in the treatment of NSCLC,and it is worth being spreaded in clinical practice.
出处
《中华保健医学杂志》
2010年第1期29-31,共3页
Chinese Journal of Health Care and Medicine
关键词
非小细胞肺癌
吉非替尼
疗效
安全性
Non-small cell lung cancer
Gefitinib
Clinical curative effect
Safety
